Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial

Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial

(2016) PM Girard et al.   HIV MEDICINE

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2016) Huldrych F. Günthard et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

(2016) J. A. Perez-Molina et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV

(2016) Alison L. Hill et al.   PLoS Pathogens

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial

(2016)   Lancet HIV

Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial

(2016) Torsak Bunupuradah et al.   Lancet HIV

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients

(2016) Jean-Guy Baril et al.   PLoS One

Four days a week or less on appropriate anti-HIV drug combinations provided long-term optimal maintenance in 94 patients: the ICCARRE project

(2015) Jacques Leibowitch et al.   FASEB JOURNAL

Efficacy of protease inhibitor monotherapyvs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials

(2015) JR Arribas et al.   HIV MEDICINE

Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons

(2015) L Ryom et al.   HIV MEDICINE

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

(2015) José R Arribas et al.   LANCET INFECTIOUS DISEASES

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study

(2015)   LANCET INFECTIOUS DISEASES

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission

(2015) Mykola Pinkevych et al.   PLoS Pathogens

Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial

(2015) Nicholas I Paton et al.   Lancet HIV

Significant Reduction in HIV Virologic Failure During a 15-Year Period in a Setting With Free Healthcare Access

(2014) C. Delaugerre et al.   CLINICAL INFECTIOUS DISEASES

HIV-1 DNA predicts disease progression and post-treatment virological control

(2014) James P Williams et al.   eLife

Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies

(2013) Susanne Eriksson et al.   PLoS Pathogens

Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study

(2013) Asier Sáez-Cirión et al.   PLoS Pathogens

Psychometric Validation of the PROQOL-HIV Questionnaire, a New Health-Related Quality of Life Instrument–Specific to HIV Disease

(2012) Martin Duracinsky et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Tenofovir, Emtricitabine Intracellular and Plasma, and Efavirenz Plasma Concentration Decay Following Drug Intake Cessation

(2012) Akil Jackson et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

The Advantages of Therapeutic Drug Monitoring in Patients Receiving Antiretroviral Treatment and Experiencing Medication-Related Problems

(2012) Joan A. Schoenenberger et al.   THERAPEUTIC DRUG MONITORING

Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study

(2011) M. A. Valantin et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A Randomized, Controlled, Trial of Short Cycle Intermittent Compared to Continuous Antiretroviral Therapy for the Treatment of HIV Infection in Uganda

(2010) Steven J. Reynolds et al.   PLoS One

Short-Cycle Therapy in Adolescents after Continuous Therapy with Established Viral Suppression: The Impact on Viral Load Suppression

(2009) Bret J. Rudy et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Not All Missed Doses Are the Same: Sustained NNRTI Treatment Interruptions Predict HIV Rebound at Low-to-Moderate Adherence Levels

(2008) Jean-Jacques Parienti et al.   PLoS One

O214 The FOTO study: 24-week results support the safety of a 2-day break on efavirenz-based antiretroviral therapy

(2008) C Cohen et al.   Journal of the International AIDS Society